JP2022506113A5 - - Google Patents

Info

Publication number
JP2022506113A5
JP2022506113A5 JP2021523282A JP2021523282A JP2022506113A5 JP 2022506113 A5 JP2022506113 A5 JP 2022506113A5 JP 2021523282 A JP2021523282 A JP 2021523282A JP 2021523282 A JP2021523282 A JP 2021523282A JP 2022506113 A5 JP2022506113 A5 JP 2022506113A5
Authority
JP
Japan
Prior art keywords
composition according
oxybutynin
hydroxyatomoxetine
receptor antagonist
muscarinic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506113A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043065 external-priority patent/WO2020091862A1/en
Publication of JP2022506113A publication Critical patent/JP2022506113A/ja
Publication of JP2022506113A5 publication Critical patent/JP2022506113A5/ja
Priority to JP2024062027A priority Critical patent/JP2024088740A/ja
Pending legal-status Critical Current

Links

JP2021523282A 2018-10-31 2019-07-23 睡眠時無呼吸を治療するための方法及び組成物 Pending JP2022506113A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024062027A JP2024088740A (ja) 2018-10-31 2024-04-08 睡眠時無呼吸を治療するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753420P 2018-10-31 2018-10-31
US62/753,420 2018-10-31
PCT/US2019/043065 WO2020091862A1 (en) 2018-10-31 2019-07-23 Methods and compositions for treating sleep apnea

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024062027A Division JP2024088740A (ja) 2018-10-31 2024-04-08 睡眠時無呼吸を治療するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2022506113A JP2022506113A (ja) 2022-01-17
JP2022506113A5 true JP2022506113A5 (cg-RX-API-DMAC7.html) 2022-07-27

Family

ID=67539629

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523282A Pending JP2022506113A (ja) 2018-10-31 2019-07-23 睡眠時無呼吸を治療するための方法及び組成物
JP2024062027A Pending JP2024088740A (ja) 2018-10-31 2024-04-08 睡眠時無呼吸を治療するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024062027A Pending JP2024088740A (ja) 2018-10-31 2024-04-08 睡眠時無呼吸を治療するための方法及び組成物

Country Status (9)

Country Link
US (4) US20210401790A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873454A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022506113A (cg-RX-API-DMAC7.html)
KR (1) KR20210084481A (cg-RX-API-DMAC7.html)
CN (1) CN112930179A (cg-RX-API-DMAC7.html)
AU (1) AU2019370091A1 (cg-RX-API-DMAC7.html)
CA (1) CA3117766A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021004883A (cg-RX-API-DMAC7.html)
WO (1) WO2020091862A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523876A (ja) * 2021-06-17 2024-07-02 アプニメッド,インコーポレイテッド(デラウェア) 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤
MX2024007768A (es) * 2021-12-22 2024-07-01 Bayer Ag Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o.
IL313648A (en) * 2021-12-22 2024-08-01 Bayer Ag Combination of a TASK1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
CN119789855A (zh) * 2022-09-02 2025-04-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
AT414238B (de) * 2001-03-06 2006-10-15 Lilly Co Eli Neues hydroxyliertes 3-phenoxy-3-phenyl-1- aminopropan und dieses aminopropan enthaltende pharmazeutische formulierung
PT1691811E (pt) * 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
JP2012176958A (ja) * 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc (r)−オキシブチニンおよび(r)−デスエチルオキシブチニンによる平滑筋機能亢進の処置
EP4011370A1 (en) * 2014-07-22 2022-06-15 Magnolia Cns, Llc Pharmaceutical compositions and method for the treatment of symptoms of panic and anxiety using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations
CN119185558A (zh) * 2017-04-28 2024-12-27 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物

Similar Documents

Publication Publication Date Title
CN101730530B (zh) 他喷他多的滴定
US20260014163A1 (en) Use of reboxetine to treat fibromyalgia
US8512751B2 (en) Pharmaceutical compositions for sleep disorders
JP6479670B2 (ja) 7,8−ジヒドロキシフラボンおよび7,8−置換フラボン誘導体、組成物、およびそれらに関連する方法
JP2020517719A5 (cg-RX-API-DMAC7.html)
JP2019116494A (ja) アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
JPH08208471A (ja) 薬物反応の増強作用
JP2008524332A5 (ja) 睡眠障害のための医薬組成物
JP2022519721A5 (cg-RX-API-DMAC7.html)
JP2025084754A5 (cg-RX-API-DMAC7.html)
US12115165B2 (en) Use of reboxetine to treat narcolepsy
RS51452B (sr) Orodisperzivne farmaceutske smeše za oralnu, oromukozalnu ili sublingvalnu primenu agomelatina
US20210100808A1 (en) Use of reboxetine to treat narcolepsy
JP2020533415A (ja) ナルコレプシーの処置におけるガボキサドールの使用
JP2006506461A (ja) ミルナシプランのパルス型放出組成物
US12616702B2 (en) Use of reboxetine to treat narcolepsy
US20070219201A1 (en) Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders
TWI790510B (zh) 瑞波西汀治療神經系統障礙的用途
JP2024511091A5 (cg-RX-API-DMAC7.html)
US20260014165A1 (en) Use of esreboxetine to treat nervous system disorders such as fibromyalgia
JP2025500344A5 (cg-RX-API-DMAC7.html)
CN116194092A (zh) 经口给予制剂
JP2025527796A (ja) 睡眠時無呼吸を治療するための方法及び組成物